Genstruct

Opulus, Ltd. is a biotechnology company focused on the development of new measurement systems based on hyphenated Quartz Crystal Microbalance for molecular biology, drug discovery, and the development of new materials for drug delivery and cosmetic treatment based on high resolution visco-elastic kinetics and in-situ cytotoxicity.

Active Pass is a Canadian biotechnology company that is engaging in genomic-based drug discovery and is developing drugs that inhibit ABC transporters. ABC or (ATP binding cassette) is a term that describes the interconnected group of molecular engines or pumps that function as a transportation system which moves compounds across the biological membranes. These ABCs are very closely associated with human diseases like Alzheimer's disease, diabetes, asthma, and hypertension. The Active Pass management team is an accomplished group with experience in many aspects of drug discovery and development. Besides employing full time pharmaceutical development professionals, Active Pass has made wise use of a group of several key partnerships with different pharmaceutical groups. The company cultivates these partnerships in order to access new capabilities or expertise to advance the company's own technologies. More specifically, these partnerships include the Vaccines and Infectious Diseases Organization as well as the National Institute of Health). The company hopes to add new personnel to cover emerging areas of emphasis like clinical and regulatory affairs, business development and finance as they grow.

Montana Molecular was founded in 2004 to develop and commercialize fluorescent proteins (FPs) for live cell imaging applications. The technology that underlies this effort was originally conceived by Thomas Hughes at Yale University. Dr. Hughes is now the head of the Department of Cell Biology and Neuroscience at Montana State University. The Company has used this technology to develop several new read-outs for pharmaceutical and biotechnology applications, including genetically encoded fluorescent markers, a system for detecting protein-protein interaction, and biosensors for cell-based high throughput drug discovery.

AVIVA develops enabling drug discovery technoSlogies by combining biochips with cell biology.

DC Biosciences, formerly Dundee Cell Products, provides pharmaceutical and biotech companies with novel technologies and proteomics services to accelerate the development of safer drugs.

Bionucleon is a drug discovery company with a technology platform to produce olibo-based therapeutics. Bionucleon's business strategy is based on a three-branch approach:nnUsing its technology, the company aims to build its own pipeline of therapeutics for inflammatory diseases and angiogenic disorders. Bionucleon collaborates with pharmaceutical and biotechnology companies to create new oligo-based therapeutics against targets of the partner's choosing. Bionucleon generates products for out-licensing at different research and development stages. Collaborative partnerships and out-licensing provide upfront and milestone payments, and generate downstream revenue through product royalties. This approach maximizes the return on the company's nknow-how and technical capability. Through drug discovery partnering in addition to developing its own product pipeline, Bionucleon aims to build corporate value and aims to reduce the financial risk as it moves forward.